References
- AhrendtHJNisandIBastianelliCEfficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg of drospirenoneContraception200674451717157101
- DiebenTOMRoumenFJMEApterDEfficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ringObstet Gynecol20021005859312220783
- DuijkersIJMKlippingCVerhoevenCHJDiebenTOMOvarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized studyHum Reprod20041926687315333593
- GuidaMDi Spiezio SardoABramanteSEffects of two types of hormonal contraception – oral versus intravaginal – on the sexual life of women and their partnersHum Reprod2005201100615608030
- MagnusdóttirEMBjarnadóttirRIÖnundarsonPTThe contraceptive vaginal ring (NuvaRing®) and hemostasis: a comparative studyContraception200469461715157790
- MillerLVerhoevenCHJ’t HoutJExtended regimens of the contraceptive vaginal ringObstet Gynecol20051064738216135576
- MilsomILeteIBjertnaesAEffects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenoneHum Reprod20062123041116763008
- MuldersTMTDiebenTOMUse of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibitionFertil Steril2001758657011334895
- O’ConnellKJOsborneLMWesthoffCMeasured and reported weight change for women using a vaginal contraceptive ring vs a low-dose oral contraceptiveContraception200572323716246655
- OddssonKLeifels-FischerBde MeloNREfficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trialContraception2005a711768215722066
- OddssonKLeifels-FischerBWiel-MassonDSuperior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel: a randomized trialHum Reprod2005b205576215539438
- RoumenFJMEApterDMuldersTMTEfficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiolHum Reprod2001164697511228213
- RoumenFJMEDiebenTOMComparison of uterine concentrations of ethinylestradiol and etonogestrel – after use of a contraceptive vaginal ring and an oral contraceptiveFertil Steril200685576216412731
- RoumenFJMEop ten BergMMTHoomansEHMThe combined contraceptive vaginal ring (NuvaRing®): first experience in daily clinical practice in the NetherlandsEur J Contracept Reprod Health Care200611142216546812
- SabatiniRCagianoRComparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptivesContraception200674220316904415
- SchaferJEOsborneLMDavisARAcceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptiveContraception2006734889216627032
- TimmerCJMuldersTMTPharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ringClin Pharmacokinet2000392334211020137
- TuppurainenMKlimscheffskijRVenholaMThe combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: a comparative studyContraception2004693899415105061
- van den HeuvelMWvan BragtAJMAlnabawyAKMComparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptiveContraception2005721687416102549
- VeresSMillerLBuringtonBA comparison between the vaginal ring and oral contraceptivesObstet Gynecol20041045556315339769
- WesthoffCOsborneLMSchaferJBleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptiveObstet Gynecol2005106899615994622